Octave Bioscience Partners with Quest Diagnostics to Enhance MS Testing Access

Octave Bioscience has entered a strategic collaboration with Quest Diagnostics to broaden patient access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test across the United States. This partnership aims to utilize Quest’s extensive nationwide specimen-collection network to provide patients with improved diagnostic capabilities for managing multiple sclerosis (MS) and other neurodegenerative conditions.

Enhancing Diagnostic Accessibility

According to Octave Bioscience, this collaboration marks a significant step in advancing the standard of care for individuals suffering from MS. The Octave MSDA Test is designed to offer insights into disease activity, thereby enabling more personalized treatment plans. By leveraging Quest Diagnostics, a prominent provider listed on the NYSE under the ticker DGX, the test will become more readily available to healthcare providers and patients nationwide.

This initiative is expected to streamline the testing process, making it easier for clinicians to assess and monitor disease progression. The collaboration aligns with Octave’s mission to improve patient outcomes through precision medicine, particularly in neurodegenerative diseases.

Significance of the Collaboration

The partnership is poised to enhance the overall patient experience by integrating advanced diagnostic services into everyday healthcare practices. Quest Diagnostics operates a comprehensive network of facilities that will facilitate the collection and analysis of MSDA test samples. This accessibility is particularly crucial for patients in underserved areas, where specialized healthcare resources may be limited.

As the prevalence of multiple sclerosis continues to rise, the need for effective monitoring tools has become increasingly urgent. By collaborating with a leader in diagnostic services, Octave Bioscience is addressing a critical gap in the management of MS, which affects millions worldwide.

Both companies are committed to ensuring that patients can access the latest diagnostic technologies, which are essential for informed treatment decisions. The collaboration is expected to not only enhance patient care but also contribute to a deeper understanding of multiple sclerosis and its impacts.

This partnership follows a trend in the healthcare industry where diagnostic companies are joining forces with innovative biotech firms to deliver cutting-edge solutions. By combining resources and expertise, these collaborations promise to revolutionize how chronic diseases are managed.

The official announcement was made on December 1, 2025, highlighting the potential for improved healthcare delivery as both companies prepare to implement this strategic initiative across the country.